Biologicals decrease psychological distress, anxiety and depression in severe asthma, despite Covid-19 pandemic

Pelaia, Corrado; Zunno, Roberta; Pelaia, Giulia

doi:10.1016/j.rmed.2022.106916

Cited by 9 publications

(7 citation statements)

References 35 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was increased stress under lockdown, especially for patients with chronic diseases [1], and the incidence of anxiety and depression for asthma patients in our study was high, which is consistent with the findings of other studies [22,23]. Previous studies in allergic patients indicate the frequency of anxiety due to the COVID-19 lockdown [24].…”

Section: Discussionsupporting

confidence: 91%

Physician education on World Asthma Day aids in disease management during the COVID-19

Cao

Zhou

Luo

et al. 2022

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Anxiety and depression can negatively affect the management of asthma. The study aimed to assess the psychosocial effects of asthma patients during COVID-19 and analyze potential risk factors and interventions.In June 2022, the “Questionnaire Star” electronic questionnaire system was used to collect data. A total of 98 asthma patients from the affiliated hospital of the medical school of Ningbo University were invited to complete the questionnaires. According to our study, the prevalence of symptoms of anxiety and depression in the asthma patients in the institution was 91.8 and 77.6%, respectively. Patients who had an asthma exacerbation in the previous two months were more likely to have anxiety symptoms (OR = 0.142 95%CI 0.025–0.820), while patients who did not participate in asthma day activities were more likely to have anxiety symptoms than those who did (OR = 0.130 95%CI 0.022–0.762).This study found that routine disease educational lectures on asthma day can successfully alleviate asthma sufferers' anxiety and depression.

show abstract

Section: Discussionsupporting

confidence: 91%

Physician education on World Asthma Day aids in disease management during the COVID-19

Cao

Zhou

Luo

et al. 2022

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

show abstract

“…A positive effect of mAb-therapy on anxiety and depression disorders in patients with severe asthma has been reported previously, without differentiation between mAb-therapy responders and non-responders. 13 Comparable to our approach, one part of the above-mentioned WATCH study by Fong et al examined the relation between the response to Omalizumab/Mepolizumab and MDD/GAD evaluated by HADS-A/D. Non-responders suffered from mental disorders more frequently.…”

Section: Discussionmentioning

confidence: 99%

“… 10–12 Previous research showed that disease management, perceived stress, anxiety and depressive symptoms improved significantly under mAb-therapy, independent of which mAb was used. 13 , 14 While the reported responder rates vary, it is universally acknowledged that a significant subset of severe asthma patients do not respond to mAb therapy. 15–17 …”

Section: Introductionmentioning

confidence: 99%

“…[10][11][12] Previous research showed that disease management, perceived stress, anxiety and depressive symptoms improved significantly under mAb-therapy, independent of which mAb was used. 13,14 While the reported responder rates vary, it is universally acknowledged that a significant subset of severe asthma patients do not respond to mAb therapy. [15][16][17] In this study, we aim to determine a possible relation between mAb-therapy response and mental health conditions, as well as to identify predictors for mAb-nonresponse or decline in mental status.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship Between the Response to Antibody Therapy and Symptoms of Depression and Anxiety Disorders in Patients with Severe Asthma

Plank¹,

Hinze²,

Campbell³

et al. 2023

JAA

View full text Add to dashboard Cite

Purpose Asthma is associated with a high prevalence of psychopathological disorders, especially depressive disorders or anxiety. In patients with uncontrolled severe asthma, monoclonal antibody (mAb)-therapy positively influenced control of mental disorders. Therefore, we evaluated the impact of antibody therapy on the burden of these mental diseases depending on responder status. Patients and Methods Data were collected retrospectively in patients with uncontrolled severe asthma (n = 82) prior to mAb-therapy (“baseline”) (omalizumab, dupilumab, benralizumab or mepolizumab). Symptoms of Major Depressive Disorder (MDD) or General Anxiety Disorder (GAD) were detected at baseline using the Hospital Anxiety and Depression Scale (HADS), as well as general sociodemographic data and lung function parameters. At 6-month (±3 month) follow-up, the burden of psychopathological symptoms under mAb-therapy was assessed using the Patient Health Questionnaire-2 (PHQ-2) and Generalized Anxiety Disorder Scale-2 (GAD-2). Response status was classified using the Biologics Asthma Response Score (BARS), assessing exacerbations, oral corticosteroid usage and asthma control test (ACT) score. Predictors for non-response to mAb-therapy were identified using linear regression analysis. Results Patients with severe asthma suffered from symptoms of MDD/GAD more often compared to the general population, with a higher prevalence among mAb therapy non-responders. mAb-responders exhibited a declining burden of MDD, better quality of life (QoL), less exacerbations, better lung function and better disease control compared to non-responders. A history of symptoms of depression was identified as a predictor for non-response to mAb-therapy. Conclusion Asthma symptoms and psychological problems are linked and more prevalent in our cohort of severe asthma patients than in the general population. Patients with signs of MDD/GAD before mAb-therapy show less mAb therapy response suggesting a negative impact of prior psychological problems on treatment response. In some patients, the score on MDD/GAD was caused by severe asthma – here symptoms decreased after effective treatment.

show abstract

“…Patella and colleagues 30 examined the effectiveness of biological agents in the treatment of comorbid depression, anxiety and the risk of suicidal thoughts in severe asthmatic patients during COVID-19 (coronavirus disease 2019) pandemic. Asthmatic patients were treated with one of three biologicals (benralizumab, mepolizumab or omalizumab).…”

Section: Pharmacology Therapymentioning

confidence: 99%

Anxiety and post-traumatic stress disorders in patients with chronic respiratory diseases

Yohannes

2023

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of review This brief critical review evaluates recent research on the impact of anxiety disorders and post-traumatic stress disorders (PTSD) on patients with chronic obstructive pulmonary disease (COPD) and asthma. In these patients, untreated anxiety and PTSD exacerbate acute symptoms, increase disability and impair quality of life. Therefore, effective interventions are also reviewed. Recent findings Anxiety disorders and PTSD are prevalent in COPD and asthma, worsen symptoms in acute exacerbations, and increase morbidity and healthcare utilization. Pulmonary rehabilitation (PR), cognitive behavioural therapy and pharmacological therapy are each effective in COPD patients with anxiety or PTSD. However, very little work examined therapy for combined anxiety and PTSD in patients with either COPD or asthma. Summary Despite the high prevalence of anxiety disorder or PTSD in patients with chronic respiratory diseases, a paucity of literature remains demonstrating the efficacy of pharmacological therapies for these conditions. This review highlights the promising benefits of PR on anxiety, but prospective trials are needed to demonstrate the efficacy of interventions with PTSD alone, or with concomitant anxiety.

show abstract

Biologicals decrease psychological distress, anxiety and depression in severe asthma, despite Covid-19 pandemic

Cited by 9 publications

References 35 publications

Physician education on World Asthma Day aids in disease management during the COVID-19

Physician education on World Asthma Day aids in disease management during the COVID-19

Relationship Between the Response to Antibody Therapy and Symptoms of Depression and Anxiety Disorders in Patients with Severe Asthma

Anxiety and post-traumatic stress disorders in patients with chronic respiratory diseases

Contact Info

Product

Resources

About